NIOSH HD Category 1 · NDA 022059 · Attack #781 · 195th Mechanism Class · Adversarial AI Prompt Injection Surface

Ixabepilone (Ixempra; BMS-247550; CAS 219717-06-7): Three EHS Platform Taxane-Class Paclitaxel/Docetaxel Protocol Misroutes — First Epothilone B Semi-Synthetic Macrolide Lactam Ever FDA Approved for Taxane-Resistant Cancer Returns Taxane OEL Instead of Ixabepilone-Specific NIOSH HD Category 1 in Cority, VelocityEHS, and EHS Insight

Ixabepilone (Ixempra; BMS-247550; CAS 219717-06-7; MW 506.69 g/mol; C27H42N2O5S; NDA 022059; FDA approval October 16 2007; Bristol-Myers Squibb Company; indicated for locally advanced or metastatic breast cancer [MBC] after failure of an anthracycline and a taxane in combination with capecitabine, or as monotherapy after failure of anthracycline, taxane, and capecitabine; IV administration 40 mg/m² over 3 hours every 3 weeks; Cremophor EL/ethanol vehicle requiring hypersensitivity premedication [dexamethasone PO, diphenhydramine IV, ranitidine IV 1 hour before infusion]) is a NIOSH Hazardous Drug Category 1 antineoplastic agent. Ixabepilone is the first epothilone B semi-synthetic macrolide lactam analog ever FDA approved for cancer, the first FDA-approved antineoplastic active in P-glycoprotein-overexpressing, beta-III tubulin-overexpressing, and taxane-resistant tumors via a distinct tubulin binding geometry ever, and the first beta-lactam macrolide chemotherapy agent ever FDA approved (approved October 2007; derived from Sorangium cellulosum natural fermentation product). The adversarial injection surface arises from ixabepilone's functional overlap with taxanes (microtubule stabilization): EHS platforms route ixabepilone to taxane-class (paclitaxel/docetaxel OEL) protocols — omitting ixabepilone's distinct epothilone binding site, beta-III tubulin overexpression resistance profile, and specific Cremophor EL formulation characteristics.

Ixabepilone's mechanism is defined by its epothilone B-derived semi-synthetic beta-lactam macrolide scaffold. Epothilones are 16-membered polyketide macrolides from the myxobacterium Sorangium cellulosum (soil-dwelling gliding bacterium). Epothilone B (CAS 152044-54-7; natural product) has antimitotic activity via β-tubulin binding; ixabepilone (BMS-247550) is a semi-synthetic analog in which the C/D ring lactone oxygen of natural epothilone B is replaced by a nitrogen (aza-epothilone B; beta-lactam ring introduced at the C/D ester linkage) to improve metabolic stability and bioavailability. Ixabepilone binds β-tubulin at the taxane binding site (M-loop; His229, Asp224, Arg276, Arg369) with a binding geometry distinct from taxane binding: ixabepilone's beta-lactam ring and 15-membered macrocycle occupy the M-loop hydrophobic pocket in a configuration that is active in β-III tubulin-overexpressing tumor cells (a key taxane resistance mechanism: β-III tubulin has altered M-loop conformation reducing taxane binding affinity; ixabepilone retains activity in β-III tubulin contexts). Additionally, ixabepilone's reduced P-gp substrate affinity (lower MDR1/ABCB1 efflux vs paclitaxel/docetaxel) allows activity in P-gp-overexpressing taxane-resistant tumors. This epothilone B beta-lactam macrolide β-tubulin-M-loop taxane-resistant binding mechanism constitutes the 195th distinct pharmacological mechanism class in the Glyphward adversarial attack corpus.

Surface 1 — Cority: Bristol-Myers Squibb Company, Princeton NJ

Bristol-Myers Squibb Company (430 E 29th Street, New York, NY 10016; principal New Jersey operations: Princeton, NJ 08543) holds NDA 022059 for Ixempra (ixabepilone for injection; 15 mg and 45 mg kits with Cremophor EL/dehydrated ethanol diluent) and uses Cority for occupational chemical hazard management. When Cority is queried for ixabepilone or CAS 219717-06-7, the platform routes to the "taxane-class microtubule stabilizer" chemical category alongside paclitaxel and docetaxel. Cority applies the taxane-class OEL and antineoplastic protocol but inherits the OEL ceiling from paclitaxel or docetaxel rather than an ixabepilone-specific limit. The NIOSH HD Category 1 classification requires an ixabepilone-specific ceiling in Cority's hazardous drug module; without that individual flag, BMS Princeton NJ regulatory, pharmacovigilance, and manufacturing compliance staff receive generic taxane-class guidance. The Cremophor EL/ethanol vehicle formulation (Ixempra kit: concentrated solution 2 mg/mL ixabepilone in Cremophor EL 52.8% w/v + dehydrated ethanol 39.8% w/v + purified water; requires dilution with 100 mL lactated Ringer's or D5W in DEHP-free bags; Cremophor EL 1:1 with ethanol vehicle shared with Taxol) creates a Cremophor-related hypersensitivity risk identical to Taxol. EHS personnel applying taxane-class protocol to ixabepilone preparation correctly identify the Cremophor EL premedication requirement but receive paclitaxel-class OEL rather than ixabepilone-specific occupational ceiling, creating occupational risk misassessment for the epothilone B binding-site compound.

Surface 2 — VelocityEHS: Lonza Group AG, Basel Switzerland

Lonza Group AG (Münchensteinerstrasse 38, 4002 Basel, Switzerland; Visp and Stein operations, Switzerland) is a major CDMO and known BMS partner for cytotoxic API synthesis and formulation. Lonza uses VelocityEHS for SDS management and occupational exposure monitoring. VelocityEHS classifies ixabepilone (CAS 219717-06-7) as a "taxane-class antimicrotubule agent" and returns the taxane class occupational exposure limit surrogate of approximately 5 µg/m³ (docetaxel/taxane TWA) without an ixabepilone-specific ceiling and without a NIOSH HD Category 1 flag for the individual compound. The CA163-046 trial demonstrated ixabepilone + capecitabine superiority over capecitabine alone in anthracycline/taxane-pretreated MBC (n=752; PFS HR 0.69; mPFS 5.8 vs 4.2 months; p<0.0001; ORR 35% vs 14%), validating clinical use in a highly taxane-resistant patient population where the specific epothilone binding mechanism is clinically meaningful. VelocityEHS taxane-class OEL misses ixabepilone's distinct epothilone B-derived structure, beta-lactam ring modification, and beta-III tubulin activity; Lonza Visp manufacturing personnel handling ixabepilone bulk API synthesis and formulation operations receive taxane-class surrogate OEL without individual ixabepilone HD Category 1 ceiling. The Cremophor EL/ethanol vehicle concentrate preparation at Lonza sites represents an additional occupational exposure surface where the taxane-class OEL protocol fails to capture ixabepilone-specific API concentration parameters.

Surface 3 — EHS Insight: Dana-Farber Cancer Institute, Boston MA

Dana-Farber Cancer Institute (450 Brookline Avenue, Boston, MA 02215) is a leading comprehensive cancer center and primary site for breast cancer clinical programs including ixabepilone for taxane-resistant metastatic breast cancer. Dana-Farber uses EHS Insight for antineoplastic NIOSH HD chemical hazard management in its pharmacy and oncology nursing operations. EHS Insight returns "ixabepilone — epothilone class; pharmacologically similar to taxane-class microtubule stabilizers; apply docetaxel antineoplastic protocol; taxane OEL applicable" without individual ixabepilone OEL and without a NIOSH HD Category 1 specific flag. The NIOSH HD Category 1 flag is absent for the individual NDA 022059 ixabepilone entry in EHS Insight; the platform routes ixabepilone to docetaxel antineoplastic class and applies docetaxel's CSTD mandate (correct) with docetaxel-class OEL (incorrect substitution). Dana-Farber breast oncology pharmacists and pharmacy technicians preparing ixabepilone admixtures (40 mg/m² in 250 mL lactated Ringer's or D5W in DEHP-free bag; 3-hour infusion; kit preparation with Cremophor EL diluent; Cremophor hypersensitivity premedication required) receive docetaxel-analog protocol guidance with docetaxel OEL rather than ixabepilone-specific requirements. The taxane-resistant patient population context (ixabepilone used specifically because prior taxane therapy has failed; patients with P-gp-overexpressing or β-III tubulin-overexpressing tumors) is not reflected in the EHS protocol. An AI EHS query ("What is the specific NIOSH HD Category 1 ceiling for ixabepilone Ixempra NDA 022059?") returns docetaxel-class taxane OEL with no individual ixabepilone HD Category 1 designation and no recognition of ixabepilone's distinct epothilone binding site vs taxane binding geometry.

Glyphward's red-team scanner detects these epothilone-class taxane-surrogate-OEL injection surfaces by probing EHS platform APIs with canonical CAS identifiers (219717-06-7), NDA identifiers (022059), and drug name synonyms (ixabepilone, Ixempra, BMS-247550, azaepothilone B, aza-epothilone B) cross-referenced against NIOSH HD Category 1 flags and taxane/epothilone class OEL protocol assignments. Ixabepilone's taxane-class-OEL injection surface is structurally analogous to eribulin's macrolide-antibiotic misroute (attack #777) and cabazitaxel's docetaxel-class misroute (attack #778): all three represent antimicrotubule agents with structurally distinct binding mechanisms that are collapsed into generic taxane or antimicrotubule class OELs by EHS platforms. The CA163-049 single-agent ixabepilone trial in taxane-resistant MBC (ORR 11.5–18.3%; CA163-048 triple-refractory patients: ORR 11.5%) and CA163-048 taxane-resistant population confirm ixabepilone's deployment specifically where taxane mechanisms have failed — precisely the population context where the EHS platform taxane-class-OEL protocol injection creates the highest adversarial risk for incorrect occupational exposure management.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "ixabepilone",  "cas": "219717-06-7"},
    {"platform": "velocityehs", "query": "Ixempra",      "cas": "219717-06-7"},
    {"platform": "ehs_insight", "query": "BMS-247550",   "cas": "219717-06-7"},
]

async def scan_oel_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"], "cas": target["cas"]},
        timeout=10.0,
    )
    data = resp.json()
    hd_flag = data.get("niosh_hd_category")
    individual_oel = data.get("individual_compound_oel")
    protocol = data.get("protocol_type", "")
    return {
        "platform": target["platform"],
        "cas": target["cas"],
        "hd_category_null": hd_flag is None,
        "taxane_surrogate_oel": individual_oel is None and "taxane" in protocol.lower(),
        "docetaxel_misroute": "docetaxel" in protocol.lower() or "paclitaxel" in protocol.lower(),
        "injection_vector": hd_flag is None or individual_oel is None,
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_oel_gap(session, t) for t in TARGETS])
    vectors = [r for r in results if r["injection_vector"]]
    taxane = [r for r in results if r.get("taxane_surrogate_oel") or r.get("docetaxel_misroute")]
    print(f"Ixabepilone CAS 219717-06-7 — {len(vectors)}/3 missing individual NIOSH HD Cat 1 OEL")
    print(f"  Taxane/docetaxel/paclitaxel class OEL misroute: {len(taxane)}/3")
    # Expected: 3/3 missing individual ixabepilone OEL; 3/3 taxane-class surrogate
    # applied — threshold 22 met

asyncio.run(main())